Impact of long-term therapy with eprosartan on the structural and functional state of the heart and large vessels and on the autonomic regulation of circulation in patients with arterial hypertension

To examine the effects of eprosartan on the remodelling of the heart and large vessels, on endothelial dysfunction and autonomic circulatory regulation in patients with hypertensive disease, thirteen patients were included into the study: Doppler echocardiographic study and evaluation of left ventricular diastolic function were performed on a Vingmed CFM800 apparatus: the thickness of the carotid intima-media complex and the diameter of the brachial artery were determined on the same apparatus using a 7.5-MHz transducer in the reactive hyperemia test. Automatic balance was evaluated by the spectral assay of cardiac rhythm variations. The cardiopulmonary component of baroreflex was also tested. Blood pressure normalized in 3 patients following 24 weeks of therapy with eprosartan in a daily dose of 600 mg. Two patients were excluded due to therapeutic inefficiency. In the remaining patients, the antihypertensive effect was incomplete. The mass of the left myocardial myocardium decreased by 10.8%. there was an increase in brachial arterial dilatation in the reactive hyperemia test. The variations of cardiac rhythm were not significantly changed, the baroreflex tended to be decreased. Thus, long-term eprosartan therapy improves the structural and functional state of the heart and vessels and fails to affect the autonomic regulation of circulation.

arterial hypertension, left ventricular hypertrophy, remodelling of large vessels, endothelial function, autonomic cardiovascular regulation, eprosartan

1. Dablof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in tbe Losartan Intervention For Endpoint reduction in hypertension study (UFE): a randomized trial against atenolol. Lancet2002; 359:995- I 003.

2. Oblstein EH, Brooks DP, Feuerslein GZ et al. Inhibition of sympathetic outflow by tbe angiotensin Il receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 1997; 55:244-51.

3. Brooks D, Oblstein E, Ruffolo R. Pharmacology of eprosartan - an angiotensin II receptor antagonist: exploring hypothesisfrom clinical trials. Am Heart J 1999; 138: S247-S251.

4. World Health Organization - International Society of Hypertension guidelines for the management of hypertension J Hypertens, 1999; 17- 151-83.

5. Профилактика, диагностика и лечение первичной артериальной гипертонии в Российской Федерации. Клинические рекомендации. Клин. фармакол. и тер. 2000; 9:5-30.

6. De Gasparo M1 Levens N. Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotenzin-converting enzymeb Pharmacol Toxicol 1998;82:257-71.

7. Cuspidi C, Muiesan ML, Valagussa L. Comparative effects of candesartm and enalapril on left ventricular hypertrophy in patients with essential hypertension: tbe candesartan assessment in the treatement of cardiac hypertrophy (CATCH) study.J Hypertens 2002 Nov; 20 (I I): 2293-300.

8. Schiffrin EL, Hayoz D. Angiotensin U Receptor antagonists. Eds. M. Epstein, HR. Brunner. Philadelphia: Hanley Belfus INC 2001; 279-89.

9. Taddei S, Virdis A, Chiadcnii L, Salvetti A. The pivotal role of endothelium in hypertension. Medicographia 1999; Issue 59; 21:22-9-

10. Iwatsubo H, Nagano M, Sakai T et al. Converting Enzyme Inhibitor improves forearm reactive hyperemia in essential hypertension. Hypertension 1997; 29 (Pt2): 286-90.

11. Rajagopalan S, Harrison D. Reversing endothelial dysfunction with] ACE inhibitors. A new TRENDb Circulation 1996; 94:240-3.

12. Celermajer DS, Sorensen KE, Gooch VM et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-5.

13. Dohn K, GravehorstJSJarlov HV. Volume recorder during junctional states. Reports of tbe Steno Memorial Hospital and tbe Nordisk Insulin Laboratorium. Copenhagen 1956; 6:140.

14. Скардс ЯВ., Витолс АЯ. Гибкий онкометр для определения объема кровотока предплечья и голени методам венозной окклюзионной плетизмографии. Физиол.журн.СССР 1974; 10:16-8.

15. Stevens PM, Lamb LE. Effect of Lower Body Negative Pressure on the Cardiovascular System, Am J Cardiol 1965; 16:506-15-

16. Elliot WJ et al. Double-blind comparision of eprosartan and enalapril on cough and blood pressure. J Hum Hypertens 1999; 13:413-7.

17. Оганов PT, Небиеридзе AB. Метаболические эффекты блокаторов рецепторов ангиотензина II. Кардиология, 2002; 42:35-9

18. Rupp H, Jager B. The renin - angiotensin system and sympathetic nervous „system in hypertension and congestive heart failure: implicationsfor therapeutic interventions.! Clin Basic Cardiol 2001; 4:47-51.

19. Thurmann PAAngiotensin Il antagonism and the heart: valsartan in left ventricular hypertrophy. J Cardiovasc Pharmacol 1999; 33 (I): 33 -6.

20. Yoriucbi M, Akishita M, Dzau V. Recentprogress in angiotensin II type 2 receptor research in cardiovascular system Hypertension 1999; 33:613-21.

21. Sigare HM, Caret RM. The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 35’-monophosphate and ATI receptor-mediated prostaglandin E2 production in conscious rats.J Clin Invest 1996; 97:1978-82.

22. Schiffrin EL. Effects of angiotensin on vascular health and the importance of selective angiotensin receptor. International Forum cm Angiotensin 11 Receptor Antagonism, 2 -nd. Monte-Carlo 2001; Abstract Book: 12.

23. Dominiczak AF, Berry C, Brosnan MJ et al. Angiotensin 11 and superoxide formation in human arteries. International Forum on Angiotensin II Receptor Antagonism, 2-nd. Monte-Carlo 2001,Abstract Book: 5

24. Lahera V. Angiotensin 11 and atberoslerosis. International Forum on Angiotensin Il Receptor Antagonism, 2-nd. Monte-Carlo 2001 Abstract Book: 5

25. Балахонова TB, Погорелова OA, Ачыджанова ХГ. и др. Неинвазивное определение функции эндотелия у больных гипертонической болезнью в сочетании с гиперхолестеринемией. Тер. арх. 1998; 4:15—9·

26. Иванова O.B., Балахонова Τ.Β., Соболева Г,Н. и др. Состояние эндотелий-зависимой вазодилатации плечевой артерии у больных гипертонической болезнью, оцениваемое с помощью ультразвука высокого разрешения. Кардиология, 1997; 7:41-6.

27. Celermajer DS, Sorensen KE, Georgakopoulos Detal Cigarette smoking is associated with dose - related and potentially reversible impairment of endothelium - dependent dilation in healthy young adults. Circulation 1993; 88: 2149-55-

28. Paolisso G, Tagliamonte MR, Gambardella Ą ManzeUa D, Gualdiero P, Varricchio G, Verza M, Varricchio M. Losartan mediated improvement in insulin action is mainly dueto an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients.J Hum Hypertens 1997 May ; 116: 307-2.

29. Newby DE, Goodfield NE, Flapan AD, Boon NA, Fox KA, Webb DJ. Regulation of peripheral vascular tone in patients with heart failure: contribution of angiotensin II.Heart 1998 Aug; 116:134—40.

30. Head GA, Saigusa T, Mayorov DN. Angiotensin and baroreflex control of tbe circulation. Braz J Med Biol Res 2002 Sep; 35:1047-59-31. Veelken R, Hilgers KF, Scrogin KE, Mann JF, Schmieder RE. Endogenous angiotensin Il and the reflex response to stimulation of cardiopulmonary serotonin 5HT3 receptors.Br J Pharmacol 1998 Dec; 125:1761-7.

31. Pitzalis MV, De Tommasi E, Rizzon B et al. Beneficial effect of valsartan but not enalapril on sympathetic system activation in heartfailure. Citation: Eur Heart J September 2001; 22 (suppl): Abstr. 40.